Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

Clinical trial NCT02721407 · UNKNOWN

Trial details

NCT number: NCT02721407
Sponsor: Xinqiao Hospital of Chongqing
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mantle Cell Lymphoma Stage III/IV Adult Diffuse Large Cell Lymphoma Stage III/IV Follicular Lymphoma Stage III/IV Mantle Cell Lymphoma

Start date: 2016-03-01
Primary completion: 2018-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.